In this article, we will take a look at some of the best get rich quick stocks to buy now.
Everyone’s looking for that one big break, whether in their jobs or the stock market. However, some people actually wonder: Is the game-changer idea applicable to all, or do some people just get lucky? Well, there’s no single answer.
In this article, we discuss some of the stocks that have breakout potential. These stocks can make even an ordinary investor extraordinary, provided that it’s a bet worth making. The term “get-rich stocks” typically implies highly volatile stocks that are usually cheap.
As Cathie Wood once said,
“Volatility is the price you pay for extraordinary returns.”
We have often heard that high rewards come with high risks, and when fluctuations hit the market, it’s time to be prepared for volatility and not panic when the stock price drops temporarily. There’s no science behind it, just the general belief that if you want to chase big gains, you have to brace yourself for the bumpy ride.
Pixabay/Public Domain
Our Methodology
For this article, we have used the Finviz stock screener to identify stocks that have a price lower than $5 and a beta greater than 2. The upside potential of the stocks was calculated using the one-year price estimates by Yahoo Finance and then these were ranked in ascending order.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
10. Bit Digital, Inc. (NASDAQ:BTBT)
Upside potential as of July 8, 2025: 57.75%
Beta (5Y Monthly): 5.36
Earlier last week, Bit Digital, Inc. (NASDAQ:BTBT) announced that the underwriters of its previous public offering have proceeded to acquire an additional 11.25 million ordinary shares, worth around $21.4 million.
The option was fully exercised, with a total of 86.25 million shares sold during the public offering. After accounting for underwriting discounts and estimated expenses, Bit Digital, Inc. (NASDAQ:BTBT) generated roughly $162.9 million in net proceeds. The timing of this capital raise is quite noteworthy, as the company plans to purchase Ethereum. A testament to the company’s growth efforts is the stock’s 66.98% rise in the past five days.
The company is parting ways with Bitcoin and shifting its focus towards high-margin ETH staking and HPC services. The reason why BTBT is considered a “get-rich stock” is that it is now closely tied to ETH price volatility, and with just one jump, Bit Digital, Inc. (NASDAQ:BTBT) will likely move past its rough days.
Bit Digital, Inc. (NASDAQ:BTBT) is a New York-based bitcoin mining business that was incorporated in 2015. The company designs, develops, and manages high-performance computing (HPC) data centers offering not only hosting and colocation services but also cloud-based HPC graphics processing units for AI and machine learning developers.
9. Ranpak Holdings Corp. (NYSE:PACK)
Upside potential as of July 8, 2025: 74.38%
Beta (5Y Monthly): 2.71
Paul Aram has been appointed the Chief Operating Officer of Ranpak Holdings Corp. (NYSE:PACK) upon the approval of the Board of Directors on June 27, 2025. The official start date will be mutually decided.
Under the employment contract, Aram is set to receive a salary of €310,000, in addition to the target cash bonus of 40% of his basic salary, and a one-time new hire award of 5,000 performance-based restricted stock units (PRSUs) and 5,000 restricted stock units (RSUs). If he meets the eligibility criteria, he can enjoy company benefit programs just like other senior officials.
This comes at a time when Ranpak Holdings Corp. (NYSE:PACK) continues to work towards achieving 50% growth in automation revenue set for 2025. The expansion particularly comes from North America as robust enterprise accounts and automation demand have set high hopes.
Ranpak Holdings Corp. (NYSE:PACK) is an Ohio-based company that, along with its subsidiaries, delivers both product protection and end-of-line automation solutions for e-commerce and industrial supply chains. Founded in 1972, the company is dedicated to providing sustainable paper packaging solutions to safeguard people, the planet, and everything in between.
8. Dolphin Entertainment, Inc. (NASDAQ:DLPN)
Upside potential as of July 8, 2025: 273.13%
Beta (5Y Monthly): 2.27
The Chief Executive Officer of Dolphin Entertainment, Inc. (NASDAQ:DLPN), William O’Dowd IV, has acquired 4,350 shares of the company’s common stock worth $4945. According to the Form 4 filing with the Securities and Exchange Commission, a series of transactions took place at prices ranging from $1.10 to $1.18, with an average price of $1.137.
This means that O’Dowd now directly owns 231,829 shares of Dolphin Entertainment, Inc. (NASDAQ:DLPN), in addition to the indirect ownership of 54,535 shares via Dolphin Entertainment, LLC, and 62,106 shares through Dolphin Digital Media Holdings, LLC.
The company’s recent earnings set analysts’ expectations soaring as Dolphin Entertainment, Inc. (NASDAQ:DLPN) revealed plans to sustain the investments in Always Alpha and the affiliate marketing division, with the management anticipating both to “pay increasing dividends for us in 2026 and beyond, both in revenues and profits.”
Dolphin Entertainment, Inc. (NASDAQ:DLPN), headquartered in Coral Gables, together with its subsidiaries, functions as an entertainment marketing and production company. With two main segments: Entertainment Publicity and Marketing, and Content Production, the company also offers strategic marketing and publicity services to both individuals and institutions.
7. Genius Group Limited (NYSE:GNS)
Upside potential as of July 8, 2025: 280.53%
Beta (5Y Monthly): 9.84
Kevin Malone, a specialist in combating market manipulation, has been appointed the advisor to the Board of Genius Group Limited (NYSE:GNS). He also serves as the CEO and President of Malone Wealth, which is a Registered Investment Advisory Firm.
Under this appointment, Malone will play a crucial role as Genius Group Limited (NYSE:GNS) prepares to file a lawsuit alleging market manipulation, specifically involving naked short selling and spoofing. According to the company’s statement, the compensation received will be entirely in the form of shares, rather than in cash. This is what Malone refers to as “putting skin in the game,” while positioning himself alongside shareholders.
As Roger Hamilton, the CEO of Genius Group Limited (NYSE:GNS), said,
“I’m pleased to welcome Mr. Malone to the Genius team. Not only does he have extensive experience and expertise to offer our board, he also shares our passion for education.”
Genius Group Limited (NYSE:GNS), a Singapore-based company, provides an entrepreneur education system, business development tools, and management consultancy services. With two segments, namely Education and Campus, the company engages in various activities that enhance entrepreneurial learning.
6. Canaan Inc. (NASDAQ:CAN)
Upside potential as of July 8, 2025: 298.3%
Beta (5Y Monthly): 3.34
In the era of Bitcoin dominance, Canaan Inc. (NASDAQ:CAN) has announced the discontinuation of its secondary AI semiconductor segment to entirely focus on Bitcoin mining machine sales, self-mining, and consumer mining products.
This attempt to improve operations and enhance capital efficiency means that Canaan Inc. (NASDAQ:CAN) can fully leverage the growing Bitcoin demand for sustainable growth. As Nangeng Zhang, the chairman and chief executive officer of the company, stated,
“By focusing our resources and talent on the areas where we have deep expertise and competitive advantage, we aim to drive sustainable growth.”
During FY2024, the AI semiconductor business, referred to as the “ASICs for edge computing applications” in the company’s annual report, generated roughly $0.9 million in revenue while accounting for around 15% of the total operating expenses. Having said that, we can expect a fall in the expenditures for Canaan Inc. (NASDAQ:CAN) once the discontinuation happens.
Not only this, the various in-line projects, particularly the expansion of its self‑mining and North American collaborations, make Canaan Inc. (NASDAQ:CAN) a positive EV play on Bitcoin at the current levels.
Canaan Inc. (NASDAQ:CAN) is a Singapore-based company that engages in bitcoin mining machine sales, self-mining operations, and consumer mining products. Incorporated in 2013, the company also assembles and distributes mining equipment and spare parts.
5. Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)
Upside potential as of July 8, 2025: 326.8%
Beta (5Y Monthly): 2.71
Analysts at Raymond James have reinitiated coverage on Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) with an Outperform rating and a price target of $11, implying an upside potential of nearly 326%. This optimism is derived from the company’s lead drug candidate, BDTX-1535, which has demonstrated promising results in patients already treated with osimertinib.
The research firm views this efficacy as an improved first-line treatment setting, mainly for patients with non-classical mutations, where ongoing treatments have limited effectiveness. What’s even interesting is that Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) targets a niche market through BDTX-1535 in contrast to large enterprises working to address a broad range of EGFR mutations. This means that the company is prioritizing selectivity over wild-type EGFR while offering greater activity against atypical mutations.
Additionally, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) exhibits robust financials, with a cash runway adequate till at least the last quarter of FY27, thus allowing the company to maintain flexibility to lead a first-line non-small cell lung cancer study in non-classical mutations upon FDA feedback.
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), based in Massachusetts, is a clinical-stage oncology company that identifies and develops MasterKey therapies targeting patients with genetically defined tumors. Founded in 2014, the company is committed to making a significant impact on oncology through innovative science.
4. COMPASS Pathways plc (NASDAQ:CMPS)
Upside potential as of July 8, 2025: 359.54%
Beta (5Y Monthly): 2.25
ARK Invest’s ETFs, led by Cathie Wood, disclosed their daily trades on Thursday with the purchase of 125,491 shares of COMPASS Pathways plc (NASDAQ:CMPS), worth around $424,159. This transaction adds to the consistent buys in CMPS in the last few days, implying confidence in the company’s prospects.
Just recently, COMPASS Pathways plc (NASDAQ:CMPS) announced the success of its Phase 3 COMP005 trial for COMP360 in meeting its primary endpoint in patients with treatment-resistant depression. As the results outlined, even a single dose of 25 mg COMP360 led to a statistically significant reduction in symptom severity in contrast to placebo at week 6.
The company’s future looks equally promising, with the management working to discuss the preliminary COMP005 data with the U.S. Food and Drug Administration. Although there is no update regarding the review of the results yet, COMPASS Pathways plc (NASDAQ:CMPS) expects to reveal 26-week data for COMP005, after the participants have passed the initial stage, by the end of 2026.
COMPASS Pathways plc (NASDAQ:CMPS) is a London-based biotechnology company that specializes in mental health across the United States and the UK. Founded in 2020, the company is committed to making evidence-based innovation in mental health accessible to all.
3. Envoy Medical, Inc. (NASDAQ:COCH)
Upside potential as of July 8, 2025: 387.67%
Beta (5Y Monthly): 2.27
Envoy Medical, Inc. (NASDAQ:COCH) has disclosed that it has tapped into the remaining $5 million of principal available under its promissory note with GAT Funding, LLC, which is under the control of Glen Taylor, who happens to be a part of the company’s board of directors.
As the conditions of the additional draw, Envoy Medical, Inc. (NASDAQ:COCH) issued GAT Funding a warrant to acquire 750,000 shares of its Class A Common Stock, with an exercise price of $1.48 per share. This price is the same as the closing price of the stock on the date of the draw.
The shares associated with these warrants were issued via a private transaction based on exemptions from registration under Section 4(a)(2) of the Securities Act of 1933 and Rule 506 of Regulation D. In other news, Envoy Medical, Inc. (NASDAQ:COCH) has secured two new U.S. patents for its implantable hearing technology. There’s a good reason to believe that the company has a long way to go.
Envoy Medical, Inc. (NASDAQ:COCH) is a Minnesota-based hearing health company that offers medical technologies across the hearing loss spectrum. Founded in 1995, the company is committed to transforming the hearing industry.
2. Fate Therapeutics, Inc. (NASDAQ:FATE)
Upside potential as of July 8, 2025: 422.02%
Beta (5Y Monthly): 2.23
Analysts at H.C. Wainwright have reaffirmed their Neutral rating on Fate Therapeutics, Inc. (NASDAQ:FATE), while maintaining their price target of $5.00, implying an upside potential of around 358%. This was after the company presented its T819 data on lupus at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress in Barcelona, Spain.
This study, conducted in five patients, revealed that three patients with active lupus nephritis and a history of B-cell-targeted therapy were successful in achieving a primary renal response. The data’s SLEDAI-2K scores showed significant improvement within the one-, six-and-a-half-, and twelve-month periods, indicating a positive performance.
The research firm expressed its eagerness in DORIS remissions to consider FT819 a viable commercial threat. While the early signal of activity has led Fate Therapeutics, Inc. (NASDAQ:FATE) to continue its efforts to accelerate the study, particularly by enrolling at higher doses, the company finds itself on the bleeding edge of engineered cell therapy in autoimmune disease, a market that’s anticipated to reach high levels.
Fate Therapeutics, Inc. (NASDAQ:FATE) is a California-based clinical-stage biopharmaceutical company that focuses on the development of programmed cellular immunotherapies for people living with cancer and immune disorders. Incorporated in 2007, the company is committed to improving the lives of many.
1. Aptevo Therapeutics Inc. (NASDAQ:APVO)
Upside potential as of July 8, 2025: 13,451.61%
Beta (5Y Monthly): 5.73
As per the announcement last Tuesday, Aptevo Therapeutics Inc. (NASDAQ:APVO) has regained compliance with the Nasdaq Listing Rule 5550(b)(1), which requires listed companies to sustain at least $2.5 million in stockholders’ equity.
The company received a green signal from the Nasdaq’s Listing Qualifications Staff after previously disclosing that it was not in compliance for the quarter ended March 31, 2025. The approval was gained when Aptevo Therapeutics Inc. (NASDAQ:APVO) raised approximately $15.9 million in gross proceeds through additional equity capital during the recent quarter.
With this boost, Aptevo Therapeutics Inc. (NASDAQ:APVO) believes that it has achieved the $2.5 million mark in stockholders’ equity, meeting the listing prerequisites for The Nasdaq Stock Market LLC. Recently, the company announced the addition of preclinical candidate APVO455 to its core offerings, which include CD3-directed candidates built on the CRIS-7-derived CD3 binding domain approach. With a vision to address hematologic and solid tumors, this micro-cap company is in the right direction to outperform analysts’ expectations.
Aptevo Therapeutics Inc. (NASDAQ:APVO) is a Washington-based clinical-stage research and development biotechnology company that discovers and develops immunotherapeutic solutions targeting various cancers in the United States. Founded in 2016, the company utilizes ADAPTIR and ADAPTIR-FLEX platforms to advance its lead candidates.
While we acknowledge the potential of APVO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than APVO and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
